Compare UTHR & AVY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | AVY |
|---|---|---|
| Founded | 1996 | 1935 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 13.1B |
| IPO Year | 1999 | N/A |
| Metric | UTHR | AVY |
|---|---|---|
| Price | $488.92 | $179.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $495.08 | $200.27 |
| AVG Volume (30 Days) | 424.3K | ★ 743.0K |
| Earning Date | 10-29-2025 | 10-22-2025 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | ★ 16.08 | 5.74 |
| EPS | ★ 26.38 | 8.81 |
| Revenue | $3,128,400,000.00 | ★ $8,770,000,000.00 |
| Revenue This Year | $13.64 | $2.45 |
| Revenue Next Year | $5.78 | $4.28 |
| P/E Ratio | ★ $18.55 | $20.36 |
| Revenue Growth | ★ 13.50 | 1.03 |
| 52 Week Low | $266.98 | $156.23 |
| 52 Week High | $492.62 | $206.45 |
| Indicator | UTHR | AVY |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 63.94 |
| Support Level | $470.13 | $171.03 |
| Resistance Level | $492.62 | $173.17 |
| Average True Range (ATR) | 10.72 | 3.63 |
| MACD | -0.53 | 0.63 |
| Stochastic Oscillator | 89.55 | 97.02 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.